Nivolumab (Opdivo®) as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.
|NCPE assessment process
|Rapid review received||28/06/2017|
|Rapid review completed||10/08/2017|
|Rapid Review outcome||Full pharmacoeconomic assessment recommended|
|Full pharmacoeconomic assessment commissioned by HSE||06/09/2017|
|Pre-submission consultation with applicant||23/10/2017|
|Current Status||Awaiting applicant submission|